deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00002874

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE

Sponsor: NRG Oncology

Conditions Prostate Cancer
Interventions bicalutamide placebo radiation therapy
Updated 16 times since 2017 Last updated: May 23, 2022 Started: Feb 28, 1998 Primary completion: Aug 31, 2015 Completion: May 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prostate Cancer and is currently completed. NRG Oncology leads this study, which shows 16 recorded versions since 1998 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Dec 2019 · 9 months · monthly snapshot~Dec 2019 – ~Sep 2020 · 9 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~May 2023 · 10 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jul 2022 — May 2023 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

▶ Show 11 earlier versions

  1. Apr 2022 — Jul 2022 [monthly]

    Unknown Status PHASE3

  2. Oct 2021 — Apr 2022 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  3. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Feb 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NRG Oncology
  • National Cancer Institute (NCI)
  • Radiation Therapy Oncology Group
  • SWOG Cancer Research Network
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Allentown, United States , Amarillo, United States , Anderson, United States , Ann Arbor, United States , Annapolis, United States , Arlington Heights, United States , Atlanta, United States and 171 more locations